News
Press Releases and Media
Relationship Between Myocardial 124I-evuzamitide Uptake and Extracellular Volume Fraction: A Cardiac PET/MRI Study
Uptake of Iodine (124I) Evuzamitide in Patients with AL and ATTR Amyloidosis and Correlation with Echocardiographic Parameters
Automatic quantification of AL and ATTR amyloidosis disease burden using 124I-evuzamitide, a novel radiotracer
Relationship Between Myocardial Amyloid Load Measured by 124I-evuzamitide and Prognostic Staging Systems in Transthyretin Amyloid Cardiomyopathy
Characterizing Renal Involvement in Light Chain Amyloidosis on 124I-evuzamitide PET/MRI Imaging
Quantitative Uptake of 124I-Evuzamitide on PET Correlates with Markers of Transthyretin Cardiac Amyloidosis, Quality of Life, and Functional Status
Cardiac Involvement in Rare Forms of Amyloidosis Assessed Using 124I-Evuzamitide PET/CT
Temporal Changes in Cardiac Amyloid Burden Assessed Using 124I-Evuzamitide PET/CT
Preliminary Evaluation of 99mTc-Labeled Peptide p5+14 (AT-05) for the Detection of Cardiopulmonary Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging
Utilizing 124I-Evuzamitide PET/MRI to Elucidate the Relationship between Renal Dysfunction and Amyloid Deposition in Transthyretin Amyloid Cardiomyopathy
First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis
Changes in Organ-Specific Amyloid Load Assessed by Serial PET/CT Imaging of Iodine (124I) Evuzamitide – Correlation with Serum Biomarkers
Temporal Changes in the Renal Cytokine Profile in Response to AA Amyloidosis Induce Macrophage Infiltration Enabling Host-Mediated Targeting of Therapeutic Chimeric Antigen Receptor Macrophages (CARM)
Characterization of the Peptide-Antibody Fusion, AT-02- Studies to Support its Use as an Immunotherapy in Patients with Amyloidosis
Cardiac Amyloid Quantification Using 124I-Evuzamitide PET/CTCompared With 18F-Florbetapir PET/CT
Iodine-124-Evuzamitide PET/CT in Systemic Amyloidosis: Safety Evaluation & Reproducibility of Cardiac Uptake Quantitation
First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis
Relationship Between Myocardial 124I-evuzamitide Uptake and Cardiac Structure and Function: A Cardiac PET/MRI Study
Quantitative assessment of changes in cardiac and extracardiac amyloid load in patients with AL and ATTR amyloidosis, measured by PET/CT imaging using the pan-amyloid reactive radiotracer iodine (124I) evuzamitide
124I-evuzamitide PET/MR Unveils Hypertrophic Cardiomyopathy in a Patient with Renal AL Amyloidosis
I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate forthe Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis
I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate for the Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis
Development of Brain Shuttle Enabled AT-04, a Novel Peptibody That Binds Neuropathologic Fibrillar Aggregates
Quantification of Left Ventricular Amyloid in AL and ATTR Amyloid Cardiomyopathy: A Pilot 124I-p5+14 (AT-01) PET/CT and Echocardiography Study
Preclinical characterization of AT-04, a pan-amyloid-binding Fc domain-peptide fusion, to serve as an opsonin for macrophage-mediated clearance of amyloid deposits
AT-03 Demonstrated Pan-amyloid Binding and Stimulated the Removal of Amyloid Deposits through Macrophage-Mediated Phagocytosis
Quantitative changes in organ-specific amyloid load in a patient with AL amyloidosis,measured by 124I-AT-01 PET/CT imaging, correlate with serumbiomarkers
Quantification of left ventricular amyloid using 124I-p5+14 (AT-01) and 18F-florbetapir positron emission tomography in AL and ATTR amyloidosis
Differentiation of ATTR amyloidosis based on abdominothoracic organ-specific uptakeof 124I-AT-01 (124I-p5+14)assessed by PET/CT imaging
A kit method for direct radiolabeling the amyloid reactive peptide p5+14 with technetium-99m (99mTc) for the detection of cardiac amyloidosis by SPECT/CTimaging
Detection of extracardiac amyloid in patients with ATTR amyloidosis by PET/CT imaging using the amyloidophilic radiotracer 124I-AT-01 (124I-p5+14)
Development of novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance
Preclinical characterization of AT-02, a pan-amyloid-binding immunoglobulin-peptide fusion protein capable of enhancing phagocytosis and facilitating reduction of amyloid
Pan-amyloid reactivity of radioiodinated peptide 124I-AT-01 in patients with systemic amyloidosis demonstrated by PET/CT imaging
Results of the first-in-human PET/CT imaging study of the amyloid-reactive peptide 124I-AT-01 (124I-p5+14) for the detection of systemic amyloidosis
Final Results Of The First-In-Human Study Of The Amyloid-Reactive Peptide 124I-p5+14, (Iodine[124I] Evuzamitide; AT-01) For The Detection Of Systemic Amyloidosis
Repeat PET/CT Imaging of a Patient with Systemic Amyloidosis Using iodine (124I) evuzamitide (124I-p5+14) Identifies Organ-Specific Amyloid Regression
Fully Automated 3D Segmentation and Quantitation of the Amyloidophilic Radiotracer Iodine Evuzamitide (124i-P5+14, AT-01) in the Heart of Patients with Systemic Amyloidosis and Healthy Subjects
Detection of Cardiac Amyloidosis in Patients with Systemic AL and ATTR Amyloidosis Using Iodine Evuzamitide PET/CT Imaging and the Correlation with Serum NT-proBNP
Detection of Systemic AL Amyloidosis by 124I-p5+14 PET/CT imaging – Providing the Complete Picture for Diagnosis
Pre-Clinical Characterization of a Novel Fusion Protein (AT-03), with Pan-Amyloid Binding and Removal
Synthesis of 99m Tc-labeled Peptide p5+14 for Detection of Cardiac Amyloidosis – Preclinical Studies in a Mouse Model
Poster Number 3007
